More RSV Vaccines On the Way to Tackle Rising Need
Exciting news! Sanofi and AstraZeneca are ramping up RSV vaccine production with an extra 230,000 doses for infants from January. This comes after collaboration between vaccine makers and the Biden administration, tackling the surge in demand for RSV options for kiddos.
Here at Folia, we know the importance of both health and family, especially around the holidays. For families with infants and toddlers specifically, RSV can be a worry around this time of year, due to people spending more time inside, plus more time traveling and around new people. Sanofi and AstraZeneca's move is well-aligned with our goal to keep you in the loop with real-time info and tools for smart health decisions.
These extra doses tag along with the 77,000 doses of AstraZeneca and Sanofi's RSV monoclonal antibody, Beyfortus, dropped last month (monoclonal antibodies are designed to provide more immediate relief than vaccines do).
The White House is still in active collaboration with vaccine makers, planning strategies for the fall and gearing up for the 2024-25 season to handle the expected demand. Folia's right there with you, recognizing the need to plan ahead and providing the insights and tools to roll with the healthcare changes.
In these evolving times, Folia is your partner in managing chronic conditions as effectively as we can. Stay in the know, and stay healthy this holiday season and into the new year!